Study of MAR001 in Adults With Metabolic Dysfunction

• Status: Not yet recruiting
• Trial end date: 2024-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of multiple doses of MAR001in adult volunteers with metabolic dysfunction.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Marea Therapeutics

Criteria

Inclusion Criteria:

• Willingness to provide informed consent and comply with the intervention

• Women of childbearing potential and men agreeing to use an appropriate method of contraception for the duration of the study

• Evidence of metabolic dysfunction at screening (triglyceride levels > 2.8 mmol/L)

Exclusion Criteria:

• Any condition which in the opinion of the investigator prevents the participant from complying with study procedures or prevents the participant from completing the study or interferes with the interpretation of study results

• Pregnant or breastfeeding mothers

• Terminal illness with expected survival of less than 1 year

Note: additional inclusion/exclusion criteria may apply, per protocol